Best 5 & Worst 5 Biotech Stocks: Savient, Rexahn, Hemispherx, Novavax, EXACT Sciences, Enzon, Affymax, Infinity, Gilead Sciences, MannKind

Savient Pharmaceuticals Inc (NASDAQ:SVNT) traded 28.44% higher to close last trading session at $0.840, seemingly on a technical play as there was no major news. The stock’s year-to-date performance now stands around -20%.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) traded 20.00% higher to close last trading session at $0.390 after a Seeking Alpha blog post claimed the company is making rapid progress manipulating the elusive cancer fighting Akt-1 pathway in clinical trials for solid tumors. The stock’s year-to-date performance now stands around 25.81%.

Hemispherx BioPharma, Inc (NYSEMKT:HEB) traded 15.92% higher to close last trading session at $0.276. The stock continued to move higher seemingly on a technical play as there was no strong catalyst. The stock’s year-to-date performance now stands around 10.01%.

Novavax, Inc. (NASDAQ:NVAX) traded +6.70% higher to close last trading session at $1.91 amid news that its partner, Cadila Pharmaceutical, aimed at launching vaccine for Influenza H1N1 A Virus (swine flu) in India will seek the government’s nod in two days for initiating clinical trials in this regard. The stock’s year-to-date performance now stands around +1.06%.

EXACT Sciences Corporation (NASDAQ:EXAS) traded 2.51% higher to close last trading session at $11.84 after its presentation at Jefferies Global Healthcare Conference. The stock’s year-to-date performance now stands around +11.8%.

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) traded 49.69% lower to close last trading session at $1.60 after reaching ex-dividend date on Wednesday. The stock’s year-to-date performance now stands around -63.88%.

Affymax, Inc (NASDAQ:AFFY) traded -23.08% lower to close last trading session at $1.20 as was approaching NASDAQ delisting on June 6th 2013. The stock’s year-to-date performance now stands around -93.68%.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded -5.68% lower to close last trading session at $19.11, losing ground again after the company’s ASCO oral presentation of IPI-145 Phase I data in lymphoma patients. The stock’s year-to-date performance now stands around -45.4%.

Gilead Sciences, Inc. (NASDAQ:GILD) traded -4.20% lower to close last trading session at $50.12, extending fall after presenting data on its experimental leukemia drug. The stock’s year-to-date performance now stands around -36.49%.

MannKind Corporation (NASDAQ:MNKD) traded -3.26% lower to close last trading session at $7.43 after its presentation at the Jefferies 2013 Global Healthcare Conference in New York. The stock’s year-to-date performance now stands around 221.65%.

Email
Print